Mylan Laboratories Ltd
Mylan Laboratories Limited,incorporated in India, listed on the Bombay Stock Exchange Limited, the company is engaged in the manufacture and trading of Pharmaceuticals
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE 3.07 %
- ROE -5.35 %
- Face Value ₹
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 9.47% over past five years.
- Company has a low return on equity of -5.06% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 952 | 1,489 | 1,882 | 2,878 | 3,952 | 5,392 | 6,978 | 7,857 | 9,467 | 9,623 | 9,638 | 10,969 | |
| 797 | 1,172 | 1,611 | 2,342 | 3,177 | 4,392 | 6,100 | 7,293 | 8,485 | 8,079 | 7,811 | 9,219 | |
| Operating Profit | 155 | 317 | 271 | 536 | 776 | 1,000 | 878 | 564 | 982 | 1,544 | 1,827 | 1,750 |
| OPM % | 16% | 21% | 14% | 19% | 20% | 19% | 13% | 7% | 10% | 16% | 19% | 16% |
| -357 | 35 | 129 | 185 | 28 | 12 | 843 | 923 | 619 | 357 | 505 | 296 | |
| Interest | 29 | 59 | 54 | 43 | 58 | 63 | 248 | 569 | 716 | 857 | 817 | 828 |
| Depreciation | 30 | 36 | 46 | 60 | 78 | 96 | 346 | 852 | 1,191 | 1,681 | 1,806 | 1,567 |
| Profit before tax | -260 | 257 | 299 | 617 | 668 | 853 | 1,127 | 67 | -306 | -637 | -291 | -349 |
| Tax % | 15% | 26% | 29% | 25% | 30% | 39% | 25% | -99% | -56% | -26% | 14% | 17% |
| -298 | 189 | 214 | 466 | 469 | 520 | 845 | 134 | -135 | -470 | -331 | -408 | |
| EPS in Rs | -19.30 | 12.22 | 13.68 | 29.79 | 30.01 | 33.23 | 54.04 | 8.59 | -8.62 | -30.03 | -21.16 | -26.11 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 0% |
| TTM: | -19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -6% |
| 3 Years: | -5% |
| Last Year: | -5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 31 | 31 | 31 | 31 | 31 | 31 | 37 | 38 | 49 | 49 | 49 | 49 |
| Reserves | 649 | 847 | 1,121 | 1,602 | 1,822 | 2,455 | 4,142 | 4,675 | 6,777 | 8,064 | 7,646 | 7,126 |
| 443 | 648 | 612 | 836 | 1,212 | 1,800 | 6,627 | 6,974 | 10,950 | 9,283 | 8,555 | 8,582 | |
| 341 | 442 | 697 | 1,132 | 1,526 | 1,769 | 3,583 | 3,130 | 3,331 | 2,758 | 3,146 | 3,405 | |
| Total Liabilities | 1,465 | 1,968 | 2,461 | 3,601 | 4,592 | 6,057 | 14,389 | 14,817 | 21,106 | 20,154 | 19,395 | 19,162 |
| 476 | 613 | 858 | 1,153 | 1,355 | 1,800 | 6,220 | 6,010 | 10,809 | 10,138 | 9,076 | 7,948 | |
| CWIP | 115 | 148 | 133 | 77 | 110 | 131 | 1,021 | 941 | 805 | 762 | 367 | 328 |
| Investments | 232 | 232 | 177 | 262 | 245 | 54 | 156 | 163 | 0 | 0 | 0 | 0 |
| 642 | 975 | 1,292 | 2,108 | 2,882 | 4,072 | 6,992 | 7,703 | 9,492 | 9,254 | 9,953 | 10,886 | |
| Total Assets | 1,465 | 1,968 | 2,461 | 3,601 | 4,592 | 6,057 | 14,389 | 14,817 | 21,106 | 20,154 | 19,395 | 19,162 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57 | 68 | 229 | 139 | 50 | 351 | 384 | 679 | 256 | 1,605 | 2,101 | 1,325 | |
| -277 | -222 | -174 | -331 | -341 | -835 | -5,761 | -469 | -5,794 | -569 | -632 | -372 | |
| 181 | 146 | -48 | 198 | 280 | 524 | 5,420 | -280 | 5,553 | -967 | -1,554 | -960 | |
| Net Cash Flow | -39 | -8 | 7 | 6 | -11 | 40 | 44 | -70 | 16 | 70 | -85 | -8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 120 | 94 | 71 | 97 | 86 | 118 | 99 | 121 | 137 | 137 | 122 |
| Inventory Days | 240 | 195 | 252 | 253 | 229 | 223 | 243 | 289 | 289 | 267 | 311 | 311 |
| Days Payable | 166 | 139 | 142 | 155 | 151 | 144 | 159 | 150 | 140 | 121 | 167 | 156 |
| Cash Conversion Cycle | 163 | 177 | 205 | 169 | 175 | 164 | 203 | 239 | 270 | 283 | 281 | 278 |
| Working Capital Days | 131 | 149 | 132 | 131 | 133 | 145 | 165 | 207 | 226 | 235 | 245 | 235 |
| ROCE % | 15% | 24% | 18% | 27% | 27% | 30% | 14% | 2% | 1% | 2% | 3% | 3% |
Documents
Announcements
No data available.
Annual reports
No data available.